Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease (ESRD) Patients With Type 2 Diabetes

  • End date
    Oct 18, 2023
  • participants needed
  • sponsor
    Emory University
Updated on 18 March 2022
hemoglobin a1c
finger stick
hypoglycemic agents
continuous glucose monitoring


The study is conducted to assess the efficacy of real-time CGM data in preventing hypoglycemia and hyperglycemia in patients with type 2 diabetes and end-stage kidney disease (ESKD), treated with insulin therapy and receiving hemodialysis.


The study is conducted to assess the efficacy of real-time CGM data in preventing hypoglycemia and hyperglycemia among patients with type 2 diabetes (DM2), treated with insulin and receiving hemodialysis. The study will provide novel insights into the glycemic exposure patterns among dialysis patients and will provide preliminary data for future outcomes-based studies determining the best glycemic targets for this group.

Condition End-Stage Renal Disease, Type 2 Diabetes
Treatment Dexcom G6 CGM, POC BG
Clinical Study IdentifierNCT04473430
SponsorEmory University
Last Modified on18 March 2022


Yes No Not Sure

Inclusion Criteria

Inclusion criteria
receiving hemodialysis (for at least 90 days)
adult subjects with type 2 diabetes
treated with insulin therapy [basal insulin alone (glargine U100, glargine U300, determir, degludec, NPH)], or in combination with bolus insulin (at least one or more injections of aspart, lispro, glulisine, regular insulin) or in combination with incretin therapy (sitagliptin, linagliptin)
willingness to wear the CGM
currently performing self-monitored blood glucose (at least 2 times daily)

Exclusion Criteria

current or anticipated use of stress steroids doses (prednisone ≤5mg or its equivalent is allowed)
use of sulfonylureas or thiazolidinediones alone or in combination with insulin
use of personal/real-time CGM 3 months prior to study entry (blinded CGM is allowed)
prior use of insulin pumps or hybrid close loop systems (for at least the prior 28 days)
at least 10% of time spent in clinical relevant hypoglycemia (<54 mg/dl) during blinded CGM period
significant hypoglycemia (< 40 mg/dL)
extensive skin abnormalities at insertion sites
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note